Log in

NASDAQ:ICPTIntercept Pharmaceuticals Competitors & Alternatives

$47.09
+0.57 (+1.23 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$45.08
Now: $47.09
$47.24
50-Day Range
$46.52
MA: $76.38
$92.04
52-Week Range
$44.50
Now: $47.09
$125.00
Volume1.13 million shs
Average Volume1.33 million shs
Market Capitalization$1.55 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.78

Competitors

Intercept Pharmaceuticals (NASDAQ:ICPT) Vs. AMGN, GILD, CELG, VRTX, REGN, and BIIB

Should you be buying ICPT stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Intercept Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB).

Amgen (NASDAQ:AMGN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Insider & Institutional Ownership

75.8% of Amgen shares are owned by institutional investors. Comparatively, 76.5% of Intercept Pharmaceuticals shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and target prices for Amgen and Intercept Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1111602.54
Intercept Pharmaceuticals016602.27

Amgen currently has a consensus price target of $246.08, indicating a potential downside of 4.71%. Intercept Pharmaceuticals has a consensus price target of $74.6364, indicating a potential upside of 58.50%. Given Intercept Pharmaceuticals' higher possible upside, analysts plainly believe Intercept Pharmaceuticals is more favorable than Amgen.

Earnings & Valuation

This table compares Amgen and Intercept Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.50$7.84 billion$14.8217.43
Intercept Pharmaceuticals$252 million6.16$-344,680,000.00($10.89)-4.32

Amgen has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Amgen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.

Profitability

This table compares Amgen and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen32.03%90.75%15.44%
Intercept Pharmaceuticals-127.53%-430.51%-45.23%

Summary

Amgen beats Intercept Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Risk and Volatility

Gilead Sciences has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.

Insider & Institutional Ownership

80.2% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Intercept Pharmaceuticals shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and target prices for Gilead Sciences and Intercept Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences3151002.25
Intercept Pharmaceuticals016602.27

Gilead Sciences currently has a consensus price target of $79.6538, indicating a potential upside of 4.33%. Intercept Pharmaceuticals has a consensus price target of $74.6364, indicating a potential upside of 58.50%. Given Intercept Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Intercept Pharmaceuticals is more favorable than Gilead Sciences.

Earnings & Valuation

This table compares Gilead Sciences and Intercept Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion4.27$5.39 billion$6.1412.43
Intercept Pharmaceuticals$252 million6.16$-344,680,000.00($10.89)-4.32

Gilead Sciences has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences21.84%35.44%12.84%
Intercept Pharmaceuticals-127.53%-430.51%-45.23%

Summary

Gilead Sciences beats Intercept Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Celgene (NASDAQ:CELG) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Volatility and Risk

Celgene has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Insider and Institutional Ownership

71.7% of Celgene shares are owned by institutional investors. Comparatively, 76.5% of Intercept Pharmaceuticals shares are owned by institutional investors. 0.4% of Celgene shares are owned by company insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Celgene and Intercept Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celgene06002.00
Intercept Pharmaceuticals016602.27

Celgene currently has a consensus price target of $105.60, indicating a potential downside of 2.44%. Intercept Pharmaceuticals has a consensus price target of $74.6364, indicating a potential upside of 58.50%. Given Intercept Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Celgene.

Earnings and Valuation

This table compares Celgene and Intercept Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celgene$15.28 billion5.04$4.05 billion$7.6114.22
Intercept Pharmaceuticals$252 million6.16$-344,680,000.00($10.89)-4.32

Celgene has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Celgene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Celgene and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celgene34.63%78.15%18.54%
Intercept Pharmaceuticals-127.53%-430.51%-45.23%

Vertex Pharmaceuticals (NASDAQ:VRTX) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares Vertex Pharmaceuticals and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals31.35%25.69%18.50%
Intercept Pharmaceuticals-127.53%-430.51%-45.23%

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Intercept Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion18.13$1.18 billion$4.2967.86
Intercept Pharmaceuticals$252 million6.16$-344,680,000.00($10.89)-4.32

Vertex Pharmaceuticals has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Vertex Pharmaceuticals and Intercept Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals072112.79
Intercept Pharmaceuticals016602.27

Vertex Pharmaceuticals currently has a consensus price target of $284.2308, indicating a potential downside of 2.36%. Intercept Pharmaceuticals has a consensus price target of $74.6364, indicating a potential upside of 58.50%. Given Intercept Pharmaceuticals' higher possible upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Insider and Institutional Ownership

93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Intercept Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Intercept Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Profitability

This table compares Regeneron Pharmaceuticals and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals28.56%24.94%18.81%
Intercept Pharmaceuticals-127.53%-430.51%-45.23%

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Intercept Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion8.71$2.12 billion$21.4728.99
Intercept Pharmaceuticals$252 million6.16$-344,680,000.00($10.89)-4.32

Regeneron Pharmaceuticals has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Regeneron Pharmaceuticals and Intercept Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0131312.56
Intercept Pharmaceuticals016602.27

Regeneron Pharmaceuticals presently has a consensus price target of $557.7037, suggesting a potential downside of 10.40%. Intercept Pharmaceuticals has a consensus price target of $74.6364, suggesting a potential upside of 58.50%. Given Intercept Pharmaceuticals' higher possible upside, analysts plainly believe Intercept Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Insider & Institutional Ownership

68.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Intercept Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Intercept Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Intercept Pharmaceuticals (NASDAQ:ICPT) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares Intercept Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intercept Pharmaceuticals-127.53%-430.51%-45.23%
Biogen40.76%49.22%24.26%

Analyst Recommendations

This is a summary of current ratings for Intercept Pharmaceuticals and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intercept Pharmaceuticals016602.27
Biogen517902.13

Intercept Pharmaceuticals presently has a consensus target price of $74.6364, indicating a potential upside of 58.50%. Biogen has a consensus target price of $308.5926, indicating a potential upside of 16.40%. Given Intercept Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Intercept Pharmaceuticals is more favorable than Biogen.

Earnings and Valuation

This table compares Intercept Pharmaceuticals and Biogen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intercept Pharmaceuticals$252 million6.16$-344,680,000.00($10.89)-4.32
Biogen$14.38 billion3.01$5.89 billion$33.577.90

Biogen has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

76.5% of Intercept Pharmaceuticals shares are held by institutional investors. Comparatively, 87.5% of Biogen shares are held by institutional investors. 23.7% of Intercept Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Intercept Pharmaceuticals has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Summary

Biogen beats Intercept Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.0$258.24+1.2%$151.91 billion$23.36 billion20.24Unusual Options Activity
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
1.9$76.35+0.4%$95.77 billion$22.45 billion19.63Analyst Report
Analyst Revision
Celgene logo
CELG
Celgene
1.7$108.24+0.0%$77.04 billion$15.28 billion14.22
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
1.4$291.10+1.7%$75.48 billion$4.16 billion50.45Analyst Report
Insider Selling
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
1.4$622.45+2.1%$68.48 billion$7.86 billion31.28Analyst Report
Insider Selling
Heavy News Reporting
Biogen logo
BIIB
Biogen
1.9$265.12+0.1%$43.26 billion$14.38 billion8.18
Seattle Genetics logo
SGEN
Seattle Genetics
1.3$169.03+0.9%$29.26 billion$916.71 million-89.91Analyst Report
Insider Selling
Analyst Revision
Heavy News Reporting
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.3$112.30+0.1%$24.80 billion$4.99 billion10.57Analyst Revision
Heavy News Reporting
Incyte logo
INCY
Incyte
1.4$106.47+3.6%$23.14 billion$2.16 billion-60.84Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.7$126.78+0.7%$22.93 billion$1.70 billion207.84Insider Selling
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.5$149.87+0.7%$17.29 billion$219.75 million-18.66Analyst Downgrade
EXACT Sciences logo
EXAS
EXACT Sciences
1.6$86.66+0.9%$12.99 billion$876.29 million-111.10Heavy News Reporting
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
1.8$125.37+0.4%$11.64 billion$788.10 million68.14
Immunomedics logo
IMMU
Immunomedics
1.9$37.54+1.7%$8.67 billion$290,000.00-20.51Analyst Upgrade
Unusual Options Activity
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$60.79+1.0%$8.47 billion$1.12 billion55.26Unusual Options Activity
Heavy News Reporting
Exelixis logo
EXEL
Exelixis
1.8$23.48+0.1%$7.20 billion$967.78 million25.25
Repligen logo
RGEN
Repligen
1.2$126.65+1.9%$6.62 billion$270.24 million281.45Analyst Report
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$120.33+0.6%$5.30 billion$1.45 billion10.04Analyst Downgrade
Insider Selling
Novavax logo
NVAX
Novavax
1.2$81.64+2.4%$4.73 billion$18.66 million-19.72Analyst Downgrade
Analyst Revision
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.2$84.08+2.6%$4.41 billion$1.11 billion64.68Analyst Report
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.55+0.0%$4.01 billion$182.24 million-11.96Analyst Upgrade
Insider Selling
Unusual Options Activity
Analyst Revision
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.6$28.51+3.9%$3.87 billion$195.99 million-51.84Analyst Report
Unusual Options Activity
Momenta Pharmaceuticals logo
MNTA
Momenta Pharmaceuticals
1.6$32.27+1.5%$3.80 billion$23.87 million-11.52Analyst Downgrade
Insider Selling
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$58.01+0.2%$3.59 billion$36.13 million-53.22Analyst Downgrade
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$63.10+1.0%$3.18 billion$806.43 million-9.77
Alkermes logo
ALKS
Alkermes
1.1$19.59+0.9%$3.11 billion$1.17 billion-22.26
Opko Health logo
OPK
Opko Health
1.7$3.54+3.1%$2.37 billion$901.90 million-7.38Analyst Downgrade
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$111.64+0.2%$1.79 billion$120.28 million-32.45
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$111.58+0.6%$1.72 billionN/A-16.38
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.4$10.18+0.1%$1.62 billion$428.41 million19.21Analyst Upgrade
Heavy News Reporting
Innoviva logo
INVA
Innoviva
0.9$13.99+0.4%$1.42 billion$261.02 million8.18
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.4$9.63+2.6%$1.36 billion$102.43 million-11.60Analyst Downgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$5.02+2.2%$885.53 million$48.83 million-5.34Analyst Downgrade
Myriad Genetics logo
MYGN
Myriad Genetics
1.4$11.58+2.8%$863.34 million$851.10 million-5.79
ImmunoGen logo
IMGN
ImmunoGen
1.4$4.88+2.7%$851.10 million$82.27 million-8.41
Dynavax Technologies logo
DVAX
Dynavax Technologies
2.1$8.67+4.2%$799.24 million$35.22 million-4.71Analyst Upgrade
Codexis logo
CDXS
Codexis
1.5$12.07+3.3%$712.35 million$68.46 million-48.28
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.6$3.24+0.9%$694.30 million$150,000.00-4.63Analyst Revision
Agenus logo
AGEN
Agenus
1.5$4.02+0.0%$672.88 million$150.05 million-3.24Analyst Downgrade
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
2.0$11.85+0.7%$646.42 million$227.19 million5.54Unusual Options Activity
Molecular Templates logo
MTEM
Molecular Templates
1.6$13.51+0.1%$617.82 million$22.27 million-6.23Analyst Downgrade
Heavy News Reporting
Clovis Oncology logo
CLVS
Clovis Oncology
1.7$6.61+1.2%$508.32 million$143.01 million-0.92Analyst Downgrade
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.8$62.42+1.4%$458.47 million$38.19 million18.74
Geron logo
GERN
Geron
1.2$2.17+0.9%$441.20 million$460,000.00-5.56Analyst Upgrade
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.43+7.6%$399.49 million$109.33 million-2.86Analyst Report
Heavy News Reporting
MannKind logo
MNKD
MannKind
1.9$1.79+5.6%$381.52 million$63.04 million-7.78
Progenics Pharmaceuticals logo
PGNX
Progenics Pharmaceuticals
1.5$4.10+0.0%$355.05 million$34.99 million-5.32High Trading Volume
PDL BioPharma logo
PDLI
PDL BioPharma
1.0$2.91+2.4%$339.15 million$54.76 million-3.10
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.5$1.91+6.8%$321.97 million$59.29 million-11.94
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.9$12.43+7.6%$280.36 million$3.57 million-4.20Analyst Downgrade
Analyst Revision
This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.